Omniscope‘s technology informs therapy and develops diagnostics through the convergence of high resolution immune cell sequencing and artificial intelligence. Its proprietary ultra-deep single-cell T cell receptor sequencing platform provides unprecedented data granularity. Combined with integrated advanced statistical and machine learning models, its platform permits exhaustive characterization of adaptive immune responses. Within the BAXERNA project, Omniscope will quantify the impact of M. tuberculosis mRNA vaccines on the immune system to elucidate their efficacy, aid in vaccine candidate prioritization, and validate patient response during the phase I clinical trial.